Pharmacokinetics and pharmacodynamics of 'old' polymyxins: What is new?

Diagnostic Microbiology and Infectious Disease

Volumn 74, Issue 3, 2012, Pages 213-223

  Bergen, Phillip J ^a   Landersdorfer, Cornelia B ^a   Zhang, Jing ^b   Zhao, Miao ^b   Lee, Hee Ji ^a   Nation, Roger L ^a   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

^b FUDAN UNIVERSITY   (China)

Author keywords

Colistin; Pharmacodynamics; Pharmacokinetics; Polymyxin B

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; DORIPENEM; DOXYCYCLINE; GENTAMICIN; IMIPENEM; LIPID A; LIPOPEPTIDE; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; POLYMYXIN DERIVATIVE; RIFAMPICIN; SULTAMICILLIN; TIGECYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG THERAPY, COMBINATION; HUMANS; KLEBSIELLA INFECTIONS; POLYMYXIN B; POLYMYXINS; PSEUDOMONAS INFECTIONS;

EID: 84867655439     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.07.010     Document Type: Article

References (119)

1. Adams M.D., Nickel G.C., Bajaksouzian S., Lavender H., Murthy A.R., Jacobs M.R., et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009, 53:3628-3634.
2. Aoki N., Tateda K., Kikuchi Y., Kimura S., Miyazaki C., Ishii Y., et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2009, 63:534-542.
3. Balaji V., Jeremiah S.S., Baliga P.R. Polymyxins: antimicrobial susceptibility concerns and therapeutic options. Indian J Med Microbiol 2011, 29:230-242.
4. Barnett M., Bushby S.R., Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother 1964, 23:552-574.
5. Beceiro A., Llobet E., Aranda J., Bengoechea J.A., Doumith M., Hornsey M., et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother 2011, 55:3370-3379.
6. Bergen P.J., Li J., Rayner C.R., Nation R.L. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006, 50:1953-1958.
7. Bergen P.J., Li J., Nation R.L., Turnidge J.D., Coulthard K., Milne R.W. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 2008, 61:636-642.
8. Bergen P.J., Bulitta J.B., Forrest A., Tsuji B.T., Li J., Nation R.L. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 2010, 54:3783-3789.
9. Bergen P.J., Forrest A., Bulitta J.B., Tsuji B.T., Sidjabat H.E., Paterson D.L., et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 2011, 55:5134-5142.
10. Bergen P.J., Tsuji B.T., Bulitta J.B., Forrest A., Jacob J., Sidjabat H.E., et al. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2011, 55:5685-5695.
11. Beveridge E.G., Martin A.J. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother 1967, 29:125-135.
12. Bulitta J.B., Yang J.C., Yohonn L., Ly N.S., Brown S.V., D'Hondt R.E., et al. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 2010, 54:2051-2062.
13. Campos M.A., Vargas M.A., Regueiro V., Llompart C.M., Alberti S., Bengoechea J.A. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun 2004, 72:7107-7114.
14. Cirioni O., Ghiselli R., Orlando F., Silvestri C., Mocchegiani F., Rocchi M., et al. Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. Crit Care Med 2007, 35:1717-1723.
15. Cirioni O., Ghiselli R., Silvestri C., Kamysz W., Orlando F., Mocchegiani F., et al. Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. Antimicrob Agents Chemother 2007, 51:2005-2010.
16. Clausell A., Garcia-Subirats M., Pujol M., Busquets M.A., Rabanal F., Cajal Y. Gram-negative outer and inner membrane models: insertion of cyclic cationic lipopeptides. J Phys Chem B 2007, 111:551-563.
17. Clements A., Tull D., Jenney A.W., Farn J.L., Kim S.H., Bishop R.E., et al. Secondary acylation of Klebsiella pneumoniae lipopolysaccharide contributes to sensitivity to antibacterial peptides. J Biol Chem 2007, 282:15569-15577.
18. Conway S.P., Pond M.N., Watson A., Etherington C., Robey H.L., Goldman M.H. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997, 52:987-993.
19. Cornaglia G., Giamarellou H., Rossolini G.M. Metallo-beta-lactamases: a last frontier for beta-lactams?. Lancet Infect Dis 2011, 11:381-393.
20. Couet W., Gregoire N., Gobin P., Saulnier P.J., Frasca D., Marchand S., et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 2011, 89:875-879.
21. Decolin D., Leroy P., Nicolas A., Archimbault P. Hyphenated liquid chromatographic method for the determination of colistin residues in bovine tissues. J Chromatogr Sci 1997, 35:557-564.
22. Dotsikas Y., Markopoulou C.K., Koundourellis J.E., Loukas Y.L. Validation of a novel LC-MS/MS method for the quantitation of colistin A and B in human plasma. J Sep Sci 2011, 34:37-45.
23. Dudhani R.V., Nation R.L., Li J. Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage. J Antimicrob Chemother 2010, 65:1412-1415.
24. Dudhani R.V., Turnidge J.D., Coulthard K., Milne R.W., Rayner C.R., Li J., et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010, 54:1117-1124.
25. Dudhani R.V., Turnidge J.D., Nation R.L., Li J. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 2010, 65:1984-1990.
26. Elverdam I., Larsen P., Lund E. Isolation and characterization of three new polymyxins in polymyxins B and E by high-performance liquid chromatography. J Chromatogr 1981, 218:653-661.
27. Evans M.E., Feola D.J., Rapp R.P. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother 1999, 33:960-967.
28. Falagas M.E., Bliziotis I.A., Kasiakou S.K., Samonis G., Athanassopoulou P., Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 2005, 5:24.
29. Falagas M.E., Kasiakou S.K., Kofteridis D.P., Roditakis G., Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006, 25:596-599.
30. Falagas M.E., Rafailidis P.I., Matthaiou D.K., Virtzili S., Nikita D., Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 2008, 32:450-454.
31. Falagas M.E., Rafailidis P.I., Ioannidou E., Alexiou V.G., Matthaiou D.K., Karageorgopoulos D.E., et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010, 35:194-199.
32. Fernandez L., Gooderham W.J., Bains M., McPhee J.B., Wiegand I., Hancock R.E. Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS. Antimicrob Agents Chemother 2010, 54:3372-3382.
33. Galani I., Kontopidou F., Souli M., Rekatsina P.D., Koratzanis E., Deliolanis J., et al. Colistin susceptibility testing by Etest and disk diffusion methods. Int J Antimicrob Agents 2008, 31:434-439.
34. Gales A.C., Jones R.N., Sader H.S. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011, 66:2070-2074.
35. Garonzik S.M., Li J., Thamlikitkul V., Paterson D.L., Shoham S., Jacob J., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011, 55:3284-3294.
36. Garonzik S.M., Forrest A., Thamlikitkul V., Li J., Paterson D.L., Silveira F.P., et al. Predictors of changes in renal function in critically-ill patients on colistin methanesulfonate. A-1101 Slide Session 156 2011.
37. Giacometti A., Cirioni O., Ghiselli R., Orlando F., Mocchegiani F., D'Amato G., et al. Antiendotoxin activity of antimicrobial peptides and glycopeptides. J Chemother 2003, 15:129-133.
38. Gobin P., Lemaitre F., Marchand S., Couet W., Olivier J.C. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 2010, 54:1941-1948.
39. Govaerts C., Adams E., Van Schepdael A., Hoogmartens J. Hyphenation of liquid chromatography to ion trap mass spectrometry to identify minor components in polypeptide antibiotics. Anal Bioanal Chem 2003, 377:909-921.
40. Gunderson B.W., Ibrahim K.H., Hovde L.B., Fromm T.L., Reed M.D., Rotschafer J.C. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003, 47:905-909.
41. Hancock R.E. Peptide antibiotics. Lancet 1997, 349:418-422.
42. Hancock R.E., Chapple D.S. Peptide antibiotics. Antimicrob Agents Chemother 1999, 43:1317-1323.
43. Hartzell J.D., Neff R., Ake J., Howard R., Olson S., Paolino K., et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009, 48:1724-1728.
44. Helander I.M., Kato Y., Kilpeläinen I., Kostiainen R., Lindner B., Nummila K., et al. Characterization of lipopolysaccharides of polymyxin-resistant and polymyxin-sensitive Klebsiella pneumoniae O3. Eur J Biochem 1996, 237:272-278.
45. 31P-NMR study. Mol Microbiol 1994, 11:481-487.
46. Hirsch E.B., Tam V.H. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010, 65:1119-1125.
47. Infectious Diseases Society of America Bad bugs, no drugs 2004, Infectious Diseases Society of America, Alexandria, VA. http://www.idsociety.org.
48. Infectious Diseases Society of America The 10 × '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010, 50:1081-1083.
49. Imberti R., Cusato M., Villani P., Carnevale L., Iotti G.A., Langer M., et al. Steady-state pharmacokinetics and bronchoalveolar lavage concentration of colistin in critically ill patients after intravenous colistin methanesulfonate administration. Chest 2010, 138:1333-1339.
50. Jansson B., Karvanen M., Cars O., Plachouras D., Friberg L.E. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. J Pharm Biomed Anal 2009, 49:760-767.
51. Jernigan M.G., Press E.G., Nguyen M.H., Clancy C.J., Shields R.K. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2012, 56:3395-3398.
52. Ketthireddy S., Lee D.G., Murakami Y., Stamstad T., Andes D.R., Craig W.A. In vivo pharmacodynamics of colistin against Pseudomonas aeruginosa in thighs of neutropenic mice (abstract A-1) 2007.
53. Kumarasamy K.K., Toleman M.A., Walsh T.R., Bagaria J., Butt F., Balakrishnan R., et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, 10:597-602.
54. Kwa A.L., Lim T.P., Low J.G., Hou J., Kurup A., Prince R.A., et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis 2008, 60:163-167.
55. Kwa A.L., Abdelraouf K., Low J.G., Tam V.H. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis 2011, 52:1280-1281.
56. Lee H.J., Ku C., Tsuji B.T., Forrest F., Bulitta J.B., Li J., et al. Efficacy of colistin combination therapy against multidrug-resistant Gram-negative bacteria in mouse lung and thigh infection models 2012.
57. Li J., Turnidge J., Milne R., Nation R.L., Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001, 45:781-785.
58. Li J., Milne R.W., Nation R.L., Turnidge J.D., Coulthard K., Johnson D.W. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001, 761:167-175.
59. Li J., Milne R.W., Nation R.L., Turnidge J.D., Coulthard K., Valentine J. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 2002, 46:3304-3307.
60. Li J., Milne R.W., Nation R.L., Turnidge J.D., Smeaton T.C., Coulthard K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003, 47:1766-1770.
61. Li J., Milne R.W., Nation R.L., Turnidge J.D., Coulthard K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 2003, 47:1364-1370.
62. Li J., Coulthard K., Milne R., Nation R.L., Conway S., Peckham D., et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003, 52:987-992.
63. Li J., Milne R.W., Nation R.L., Turnidge J.D., Smeaton T.C., Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004, 53:837-840.
64. Li J., Nation R.L., Milne R.W., Turnidge J.D., Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005, 25:11-25.
65. Li J., Rayner C.R., Nation R.L., Deans R., Boots R., Widdecombe N., et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005, 49:4814-4815.
66. Li J., Nation R.L., Turnidge J.D., Milne R.W., Coulthard K., Rayner C.R., et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006, 6:589-601.
67. Li Y., Lv Y., Wang S. Mohnarin report 2010: surveillance of antimicrobial resistance in non-fermenting Gram-negative bacteria. Chin J Nosocomiol 2011, 21:5133-5145.
68. Linden P.K., Kusne S., Coley K., Fontes P., Kramer D.J., Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003, 37:e154-e160.
69. Lister P.D., Wolter D.J., Hanson N.D. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009, 22:582-610.
70. Llobet E., Tomas J.M., Bengoechea J.A. Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. Microbiology 2008, 154:3877-3886.
71. Lo-Ten-Foe J.R., de Smet A.M., Diederen B.M., Kluytmans J.A., van Keulen P.H. Comparative evaluation of the VITEK 2, disk diffusion, Etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains. Antimicrob Agents Chemother 2007, 51:3726-3730.
72. Ma Z., Wang J., Gerber J.P., Milne R.W. Determination of colistin in human plasma, urine and other biological samples using LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 862:205-212.
73. Ma Z., Wang J., Nation R.L., Li J., Turnidge J.D., Coulthard K., et al. Renal disposition of colistin in the isolated perfused rat kidney. Antimicrob Agents Chemother 2009, 53:2857-2864.
74. Maalej S.M., Meziou M.R., Rhimi F.M., Hammami A. Comparison of disc diffusion, Etest and agar dilution for susceptibility testing of colistin against Enterobacteriaceae. Lett Appl Microbiol 2011, 53:546-551.
75. Marchand S., Frat J.P., Petitpas F., Lemaitre F., Gobin P., Robert R., et al. Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother 2010, 65:1836-1837.
76. Marchand S., Lamarche I., Gobin P., Couet W. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses. J Antimicrob Chemother 2010, 65:1753-1758.
77. Markantonis S.L., Markou N., Fousteri M., Sakellaridis N., Karatzas S., Alamanos I., et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 2009, 53:4907-4910.
78. Markou N., Markantonis S.L., Dimitrakis E., Panidis D., Boutzouka E., Karatzas S., et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008, 30:143-151.
79. Moffatt J.H., Harper M., Harrison P., Hale J.D., Vinogradov E., Seemann T., et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010, 54:4971-4977.
80. Moffatt J.H., Harper M., Adler B., Nation R.L., Li J., Boyce J.D. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother 2011, 55:3022-3024.
81. Mogi T., Murase Y., Mori M., Shiomi K., Omura S., Paranagama M.P., et al. Polymyxin B identified as an inhibitor of alternative NADH dehydrogenase and malate: quinone oxidoreductase from the Gram-positive bacterium Mycobacterium smegmatis. J Biochem 2009, 146:491-499.
82. Mohamed A.F., Karaiskos I., Plachouras D., Karvanen M., Pontikis K., Jansson B., et al. Application of a loading dose of colistin methanesulphonate (CMS) in critically ill patients: population pharmacokinetics, protein binding and prediction of bacterial kill. Antimicrob Agents Chemother 2012, 56:4241-4249.
83. Montero A., Ariza J., Corbella X., Domenech A., Cabellos C., Ayats J., et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004, 54:1085-1091.
84. Montero M., Horcajada J.P., Sorli L., Alvarez-Lerma F., Grau S., Riu M., et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 2009, 37:461-465.
85. Moskowitz S.M., Ernst R.K., Miller S.I. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol 2004, 186:575-579.
86. Ofek I., Cohen S., Rahmani R., Kabha K., Tamarkin D., Herzig Y., et al. Antibacterial synergism of polymyxin B nonapeptide and hydrophobic antibiotics in experimental Gram-negative infections in mice. Antimicrob Agents Chemother 1994, 38:374-377.
87. Orwa J.A., Van Gerven A., Roets E., Hoogmartens J. Development and validation of a liquid chromatography method for analysis of colistin sulphate. Chromatographia 2000, 51:433-436.
88. Orwa J.A., Govaerts C., Busson R., Roets E., Van Schepdael A., Hoogmartens J. Isolation and structural characterization of colistin components. J Antibiot 2001, 54:595-599.
89. Owen R.J., Li J., Nation R.L., Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007, 59:473-477.
90. Ozbek B., Senturk A. Postantibiotic effects of tigecycline, colistin sulfate, and levofloxacin alone or tigecycline-colistin sulfate and tigecycline-levofloxacin combinations against Acinetobacter baumannii. Chemotherapy 2010, 56:466-471.
91. Pachon-Ibanez M.E., Docobo-Perez F., Lopez-Rojas R., Dominguez-Herrera J., Jimenez-Mejias M.E., Garcia-Curiel A., et al. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010, 54:1165-1172.
92. Payne D.J., Gwynn M.N., Holmes D.J., Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007, 6:29-40.
93. Perez J.C., Groisman E.A. Acid pH activation of the PmrA/PmrB two-component regulatory system of Salmonella enterica. Mol Microbiol 2007, 63:283-293.
94. Petrosillo N., Ioannidou E., Falagas M.E. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008, 14:816-827.
95. Pintado V., San Miguel L.G., Grill F., Mejia B., Cobo J., Fortun J., et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant Gram-negative bacteria. J Infect 2008, 56:185-190.
96. Plachouras D., Giamarellos-Bourboulis E.J., Kentepozidis N., Baziaka F., Karagianni V., Giamarellou H. In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2007, 57:419-422.
97. Plachouras D., Karvanen M., Friberg L.E., Papadomichelakis E., Antoniadou A., Tsangaris I., et al. Population pharmacokinetic analysis of colistin methanesulphonate and colistin after intravenous administration in critically ill patients with Gram-negative bacterial infections. Antimicrob Agents Chemother 2009, 53:3430-3436.
98. Poudyal A., Howden B.P., Bell J.M., Gao W., Owen R.J., Turnidge J.D., et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2008, 62:1311-1318.
99. Quale J., Shah N., Kelly P., Babu E., Backer M., Rosas-Garcia G., et al. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City. Microb Drug Resist 2012, 18:132-136.
100. Queenan A.M., Pillar C.M., Deane J., Sahm D.F., Lynch A.S., Flamm R.K., et al. Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diagn Microbiol Infect Dis 2012, 73:267-270.
101. Rahal J.J. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006, 43(Suppl. 2):S95-S99.
102. Rolain J.M., Parola P., Cornaglia G. New Delhi metallo-beta-lactamase (NDM-1): towards a new pandemia?. Clin Microbiol Infect 2010, 16:1699-1701.
103. Salvatore C.M., Abdelraouf K., Hsing D.D., Tam V.H. Pharmacokinetics of polymyxin B in an infant with multidrug-resistant Klebsiella pneumoniae bacteremia. Pediatr Infect Dis J 2011, 30:537-539.
104. Souli M., Rekatsina P.D., Chryssouli Z., Galani I., Giamarellou H., Kanellakopoulou K. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates?. Antimicrob Agents Chemother 2009, 53:2133-2135.
105. Talbot G.H., Bradley J., Edwards J.E., Gilbert D., Scheld M., Bartlett J.G. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006, 42:657-668.
106. Tam V.H., Schilling A.N., Vo G., Kabbara S., Kwa A.L., Wiederhold N.P., et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005, 49:3624-3630.
107. Tan C.H., Li J., Nation R.L. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2007, 51:3413-3415.
108. Tan T.Y., Ng L.S. Comparison of three standardized disc susceptibility testing methods for colistin. J Antimicrob Chemother 2006, 58:864-867.
109. Tascini C., Gemignani G., Palumbo F., Leonildi A., Tedeschi A., Lambelet P., et al. Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J Chemother 2006, 18:648-651.
110. Tsioutis C., Kritsotakis E.I., Maraki S., Gikas A. Infections by pandrug-resistant Gram-negative bacteria: clinical profile, therapeutic management, and outcome in a series of 21 patients. Eur J Clin Microbiol Infect Dis 2010, 29:301-305.
111. Urban C., Mariano N., Rahal J.J. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother 2010, 54:2732-2734.
112. van der Heijden I.M., Levin A.S., De Pedri E.H., Fung L., Rossi F., Duboc G., et al. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins. Ann Clin Microbiol Antimicrob 2007, 6:8.
113. Velkov T., Thompson P.E., Nation R.L., Li J. Structure-activity relationships of polymyxin antibiotics. J Med Chem 2010, 53:1898-1916.
114. Wallace S.J., Li J., Rayner C.R., Coulthard K., Nation R.L. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother 2008, 52:3047-3051.
115. Wang H., Wu H., Ciofu O., Song Z., Hoiby N. Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2011, 55:4469-4474.
116. Wang H., Wu H., Ciofu O., Song Z., Hoiby N. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother 2012, 56:2683-2690.
117. Yong D., Toleman M.A., Giske C.G., Cho H.S., Sundman K., Lee K., et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009, 53:5046-5054.
118. Zak O., O'Reilly T. Animal models in the evaluation of antimicrobial agents. Antimicrob Agents Chemother 1991, 35:1527-1531.
119. Zavascki A.P., Goldani L.Z., Cao G.Y., Superti S.V., Lutz L., Barth A.L., et al. Pharmacokinetics of intravenous polymyxin B in critically-ill patients. Clin Infect Dis 2008, 47:1298-1304.